HomeCompareCKPT vs EPRT

CKPT vs EPRT: Dividend Comparison 2026

CKPT yields 46.95% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CKPT wins by $272.8K in total portfolio value
10 years
CKPT
CKPT
● Live price
46.95%
Share price
$4.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$336.2K
Annual income
$64,770.40
Full CKPT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CKPT vs EPRT

📍 CKPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKPTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKPT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKPT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKPT
Annual income on $10K today (after 15% tax)
$3,990.61/yr
After 10yr DRIP, annual income (after tax)
$55,054.84/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CKPT beats the other by $44,140.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKPT + EPRT for your $10,000?

CKPT: 50%EPRT: 50%
100% EPRT50/50100% CKPT
Portfolio after 10yr
$199.8K
Annual income
$38,805.56/yr
Blended yield
19.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CKPT
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Price Target
$4.10
-3.8% upside vs current
Range: $4.10 — $4.10
Altman Z
-8.2
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKPT buys
0
EPRT buys
0
No recent congressional trades found for CKPT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKPTEPRT
Forward yield46.95%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$336.2K$63.4K
Annual income after 10y$64,770.40$12,840.73
Total dividends collected$264.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.10$35.50

Year-by-year: CKPT vs EPRT ($10,000, DRIP)

YearCKPT PortfolioCKPT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,395$4,694.84$11,205$505.18+$4.2KCKPT
2$23,227$6,754.79$12,672$682.46+$10.6KCKPT
3$34,378$9,524.69$14,490$930.48+$19.9KCKPT
4$49,959$13,174.92$16,786$1,282.69+$33.2KCKPT
5$71,350$17,893.73$19,753$1,791.56+$51.6KCKPT
6$100,228$23,883.40$23,677$2,541.64+$76.6KCKPT
7$138,599$31,355.00$29,008$3,672.99+$109.6KCKPT
8$188,823$40,522.29$36,463$5,425.08+$152.4KCKPT
9$253,636$51,594.75$47,238$8,221.57+$206.4KCKPT
10$336,160$64,770.40$63,385$12,840.73+$272.8KCKPT

CKPT vs EPRT: Complete Analysis 2026

CKPTStock

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Full CKPT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CKPT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKPT vs SCHDCKPT vs JEPICKPT vs OCKPT vs KOCKPT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.